Evidence map›Paper›PMID 40806707›Full record

ArticleInternational journal of molecular sciences2025

PSMA-Targeted Radiolabeled Peptide for Imaging and Therapy in Prostate Cancer: Preclinical Evaluation of Biodistribution and Therapeutic Efficacy.

Ming-Wei Chen, Yuan-Ruei Huang, Wei-Lin Lo, Shih-Ying Lee, Sheng-Nan Lo, Shih-Ming Wang, Kang-Wei Chang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ming-Wei ChenDepartment of Isotope Application Research, National Atomic Research Institute, Taoyuan 32546, Taiwan.ORCID 0009-0002-1546-6877
Yuan-Ruei HuangDepartment of Isotope Application Research, National Atomic Research Institute, Taoyuan 32546, Taiwan.
Wei-Lin LoDepartment of Isotope Application Research, National Atomic Research Institute, Taoyuan 32546, Taiwan.
Shih-Ying LeeDepartment of Isotope Application Research, National Atomic Research Institute, Taoyuan 32546, Taiwan.ORCID 0009-0006-2734-2096
Sheng-Nan LoDepartment of Isotope Application Research, National Atomic Research Institute, Taoyuan 32546, Taiwan.
Shih-Ming WangDepartment of Isotope Application Research, National Atomic Research Institute, Taoyuan 32546, Taiwan.
Kang-Wei ChangTaipei Neuroscience Institute & Laboratory Animal Center, Taipei Medical University, Taipei 110301, Taiwan.ORCID 0000-0002-4476-3603

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Albumin-binding agents enhance tumor uptake of radiopharmaceuticals targeting prostate-specific membrane antigens (PSMAs) in radiotherapy. We synthesized PSMA-NARI-56, a molecule with both PSMA targeting activity and albumin-binding moiety, labeled with

Indexed as

Antigens, SurfaceGlutamate Carboxypeptidase IIPeptidesProstatic NeoplasmsRadiopharmaceuticalsAnimalsCell Line, TumorHumansLutetiumMaleMiceRadioisotopesTissue DistributionXenograft Model Antitumor AssaysAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IILutetiumLutetium-177PeptidesRadioisotopesRadiopharmaceuticalslutetium-177theranostic agent

Identifiers

PMID40806707
PMCPMC12346970

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.